By what process did OncoImmune decide this? They h
Post# of 148166
I could certainly see the FDA in the background whispering "go for full enrollment" - the analysis was of 203 of a target 270.
At least we saw the data for a short while.
Question for Ohm and others: lessons/changed expectations for CytoDyn?